cas 1613413-65-2|| where to buy methyl 4-cyclopropyl-2-fluorobenzoate

Nom du produit:methyl 4-cyclopropyl-2-fluorobenzoate

IUPAC Name:methyl 4-cyclopropyl-2-fluorobenzoate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM766112-1g	in stock	ƚŸƐ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1613413-65-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1613413-65-2; Formule moléculaire:C11H11FO2; Point de fusion:-; Code SMILES:COC(=O)C1=C(F)C=C(C=C1)C1CC1; Densité:

: Numéro de catalogue:CM766112; Poids moléculaire:194.21; Point d'ébullition:; N° Mdl:MFCD28155009; Stockage:

: Cyclopropanes; Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.

: Remibrutinib; Novartis announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib - a highly selective, oral Bruton's tyrosine kinase (BTK) inhibitor - in people with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines. In the studies, remibrutinib met all primary and secondary endpoints at Week 12. Remibrutinib is a potential 'best-in-class' BTK inhibitor. It can covalently bind to the BTK enzyme of B cells and myeloid cells. While strongly inhibiting BTK activity, it reduces the systemic exposure of the drug and reduces the risk of adverse events and drug interactions.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.